发现 N-芳基磺酰基-吲哚-2-甲酰胺衍生物作为 Galectin-3 和 Galectin-8 C 端结构域抑制剂
摘要:
半乳糖凝集素 3 和半乳糖凝集素 8 均通过识别含半乳糖的糖蛋白参与细胞粘附、迁移、凋亡、血管生成和炎症过程。抑制半乳糖凝集素 3/8 活性是治疗癌症和组织纤维化的潜在方法。在此,一系列新型N-芳基磺酰基-5-芳氧基-吲哚-2-甲酰胺衍生物被公开为半乳糖凝集素 3 和半乳糖凝集素 8 C 端结构域的双重抑制剂,具有低微摩尔水平的K d值(Cpd 53 , gal -3: K d = 4.12 μM,gal-8C: K d = 6.04 μM;Cpd 57 ,gal-3: K d = 12.8 μM,gal-8C: K d = 2.06 μM),它们是最有效和选择性的迄今为止针对 gal-3/8 亚型的非碳水化合物抑制剂。分子对接研究表明,galectin-3 中的独特氨基酸 Arg144 和 galectin-8C 中的 Ser213 可能有助于其效力和选择性。划痕试验表明,化合物53和化合物57也能够抑制
[EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2005044810A1
公开(公告)日:2005-05-19
α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I
The present study reports a series of novel potent farnesyltransferase inhibitors from chemical modifications of the lead compounds, such as compound 13n with an IC50 value of 0.0029 μM.
Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
could give a reasonable explanation for the high activity of the target compounds. The above results indicated that thiazolamide derivatives containing diphenyl ethermoiety are valuable for in-depth study to obtain high-efficiency and low-toxicity green pesticides. Graphical abstract A series of new thiazolamide derivatives containing diphenyl ethermoiety were designed and synthesized. The biological